Top

Published in:

Open Access 01-12-2016 | Research article

Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride

Authors: Josephina G. Kuiper, Irene D. Bezemer, Maurice T. Driessen, Averyan Vasylyev, Claus G. Roehrborn, Fernie J. A. Penning-van Beest, Ron M. C. Herings

Published in: BMC Urology | Issue 1/2016

Abstract

Background

Previous studies have suggested a greater benefit for various outcomes in men diagnosed with benign prostatic hyperplasia (BPH) who are treated with dutasteride than for men treated with finasteride. This study investigates whether the rates of BPH-related prostate surgery and acute urinary retention (AUR) differ between dutasteride and finasteride users in the Netherlands.

Methods

From the PHARMO Database Network, men aged ≥50 years with a dispensing of dutasteride or finasteride with or without concomitant alpha-blocker treatment between March 1, 2003 and December 31, 2011 were selected. The incidence of BPH-related prostate surgery and AUR was determined during dutasteride or finasteride treatment and stratified by type of initial BPH-treatment (5-ARI monotherapy or combination with alpha-blocker) and prescriber (general practitioner (GP) or urologist). Comparison of the incidence of BPH-related prostate surgery and AUR between the treatment groups was done by Cox proportional hazard regression.

Results

11,822 dutasteride users and 5,781 finasteride users were identified. Most users started treatment in combination with an alpha-blocker. Overall, dutasteride users had a lower risk of BPH-related prostate surgery was lower among dutasteride users than finasteride users (HR: 0.75; 95 % CI: 0.56–0.99). This lower risk among dutasteride users was also seen when stratifying by monotherapy or combination therapy (HR: 0.73; 95 % CI: 0.54–0.98 for monotherapy and HR: 0.85; 95 % CI: 0.74–0.97 for combination therapy). However, the association was only present among men treated by urologists. For AUR the rates were low and no statistical significant difference was observed between dutasteride and finasteride users.

Conclusions

The risk of undergoing BPH-related prostate surgery was lower among men using dutasteride compared to men using finasteride. The association was observed for monotherapy as well as combination therapy, however, only among men who received their prescription from a urologist.

Roehrborn CG, Rosen RC. Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily. Clin Interv Aging. 2008;3:511–24.CrossRefPubMedPubMedCentral

Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–9.PubMed

Fitzpatrick JM. The natural history of benign prostatic hyperplasia. BJU Int. 2006;97 Suppl 2:3–6. discussion 21-22.CrossRefPubMed

Roehrborn CG, Oyarzabal Perez I, Roos EP, Calomfirescu N, Brotherton B, Wang F, Palacios JM, Vasylyev A, Manyak MJ. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart((R))) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naive men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int. 2015;116:450–59.

Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F, Comb ATSG. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123–31.CrossRefPubMed

Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434–41.CrossRefPubMed

Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89:2179–84.CrossRefPubMed

Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int. 2011;108:388–94.CrossRefPubMed

McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Finasteride Long-Term Efficacy and Safety Study Group, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338:557–63.CrossRefPubMed

10.

Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004;46:488–94. discussion 495.CrossRefPubMed

11.

Fenter TC, Davis EA, Shah MB, Lin PJ. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years. Am J Manag Care. 2008;14:S154–159.PubMed

12.

Issa MM, Runken MC, Grogg AL, Shah MB. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride. Am J Manag Care. 2007;13 Suppl 1:S10–16.PubMed

13.

Cindolo L, Fanizza C, Romero M, Pirozzi L, Autorino R, Berardinelli F, Schips L. The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis. World J Urol. 2013;31:665–71.CrossRefPubMed

14.

Foundation DHD: www.dutchhospitaldata.nl. Accessed 14 June 2016.

15.

WHO International Classification of Diseases. [www.who.int]. Accessed 14 June 2016.

16.

Dutch Classification of Procedures. [www.dhd.nl]. Accessed 14 June 2016.

17.

Care ICoP: https://www.nhg.org/themas/artikelen/icpc. Accessed 25 Aug 2016.

18.

WHO Anatomical Therapeutic Chemical Classification System. [www.whocc.no]. Accessed 14 June 2016.

19.

Catalan V, Lelorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value in Health. 2000;3:417–26.CrossRefPubMed

20.

Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2007;10:149–54.CrossRefPubMed

21.

Urologie NV. Richtlijn Diagostiek en behandeling van LUTS/BPH. 2006.

22.

Dijstelbloem DALA, Schouten MA, Lagro-Janssen ALM. Benigne prostaathyperplasie in vierhuisartsenpraktijken. Vóórkomen, beleid en beloop. Huisarts Wet. 2003;46(3):133–37.

Title: Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride
Authors: Josephina G. Kuiper
Irene D. Bezemer
Maurice T. Driessen
Averyan Vasylyev
Claus G. Roehrborn
Fernie J. A. Penning-van Beest
Ron M. C. Herings
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: BMC Urology / Issue 1/2016
Electronic ISSN: 1471-2490
DOI: https://doi.org/10.1186/s12894-016-0170-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience

Coffee and caffeine intake and risk of urinary incontinence: a meta-analysis of observational studies

Genomic copy number variation association study in Caucasian patients with nonsyndromic cryptorchidism

10-Year experience regarding the reliability and morbidity of radio guided lymph node biopsy in penile cancer patients and the associated radiation exposure of medical staff in this procedure

Increased risk for urological cancer associated with anxiety disorder: a retrospective cohort study

Clinical importance of the antibiotic regimen in transrectal ultrasound-guided biopsy: quinolone versus cephalosporin